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Executive Summary
Coronary artery calcification is part of the development of
atherosclerosis; it occurs exclusively in atherosclerotic arter-
ies and is absent in the normal vessel wall. Electron-beam
computed tomography (EBCT), the focus of this document, is
a highly sensitive technique for detecting coronary artery
calcium and is being used with increasing frequency for the
screening of asymptomatic people to assess those at high risk
for developing coronary heart disease (CHD) and cardiac
events, as well as for the diagnosis of obstructive coronary
artery disease (CAD) in symptomatic patients. The use of
EBCT has the greatest potential for further determination of
risk, particularly in elderly asymptomatic patients and others
at intermediate risk. The calcium score has been advocated by
some as a potential surrogate for age in risk-assessment
models. EBCT has also been proposed as a useful technique
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for assessing the progression or regression of coronary artery
stenosis in response to treatment of risk factors such as
hypercholesterolemia.
EBCT uses an electron beam in stationary tungsten targets,
which permits very rapid scanning times. Serial transaxial
images are obtained in 100 ms with a thickness of 3 to 6 mm
for purposes of detecting coronary artery calcium. Thirty to
40 adjacent axial scans are obtained during 1 to 2 breath-
holding sequences. Current EBCT software permits quantifi-
cation of calcium area and density. Histological studies
support the association of tissue densities of 130 Hounsfield
units (HU) with calcified plaque. However, a plaque vulner-
able to fissure or erosion can be present in the absence of
calcium. Also, sex differences play a role in the development
of coronary calcium, the prevalence of calcium in women
being half that of men until age 60 years. EBCT calcium
scores have correlated with pathological examination of the
atherosclerotic plaque.
This American College of Cardiology (ACC)/American
Heart Association (AHA) Writing Group reviewed the liter-
ature on EBCT published between 1988 and 1999 and also
used information obtained when possible from articles in
press and data sets from EBCT research centers. We also
reviewed the Blue Cross/Blue Shield (BC/BS) Technology
Evaluation Center (TEC) assessment of EBCT for screening
asymptomatic patients for CAD and for diagnosing CHD in
symptomatic patients. Three members of this Writing Group
attended the recent AHA Prevention V Conference on “Iden-
tification of the High-Risk Patient for Primary Prevention,”
and one of our members is also a participant in the design of
the National Institutes of Health/National Heart, Lung, and
Blood Institute (NIH/NHLBI) forthcoming Multiethnic Study
of Atherosclerosis (MESA), which will include a prospective
assessment of EBCT in asymptomatic people.
We performed meta-analysis on the relationship between
CHD and calcium prevalence in patients undergoing EBCT
and cardiac catheterization to determine the diagnostic accu-
racy of EBCT in catheterized patients. We also performed a
meta-analysis of published data in order to compare the
diagnostic characteristics of the available alternative tests for
detecting angiographic obstructive CAD. The studies demon-
strate a high sensitivity of EBCT for CAD, a much lower
specificity, and an overall predictive accuracy of ’70% in
typical CAD patient populations. The test has proven to have
a predictive accuracy approximately equivalent to alternative
methods for diagnosing CAD but has not been found to be
superior to alternative noninvasive methods (eg, SPECT
[single photon emission computed tomography] imaging).
The majority of the members of the Writing Group would not
recommend EBCT for diagnosing obstructive CAD because
of its low specificity (high percentage of false-positive
results), which can result in additional expensive and unnec-
essary testing to rule out a diagnosis of CAD. The 1999
ACC/AHA Coronary Angiography Guideline Committee
reached a similar conclusion (1).
Because the severity of coronary atherosclerosis is known
to be associated with risk of coronary events, coronary
calcium scores should likewise correlate with risk for coro-
nary events. However, for a test to be most valuable when
asymptomatic patients are screened, it should increase the
likelihood of CHD above the probability determined by
standard and readily available assessments, such as the
Framingham risk model based on levels of blood pressure,
cholesterol, high-density lipoprotein (HDL) cholesterol, cig-
arette smoking, plasma glucose, and age. The published
literature does not completely answer the question of whether
the EBCT calcium score is additive to the Framingham score
for defining CHD risk in asymptomatic patients. In one recent
large study (2), the addition of EBCT data provided no
incremental value to the risk determined by the Framingham
and National Cholesterol Education Program risk factors in a
direct comparison. There have been other studies that exam-
ine this point (2–4), but those reports did not adequately test
whether EBCT scores were incremental to the other risk
factor data. This is an area of important current investigation,
including the NIH/NHLBI’s MESA study. It is possible that
a positive calcium score might be valuable in determining
whether a patient who appears to be at intermediate CHD risk
is actually at high risk. Conversely, a low or absent EBCT
calcium score may also prove useful in determining a low
likelihood of developing CHD. This may be particularly
beneficial in elderly asymptomatic patients in whom the
management of other risk factors may be modified according
to the calcium score. Selected use of coronary calcium scores
when a physician is faced with the patient with intermediate
coronary disease risk may be appropriate. However, the
published literature does not clearly define which asymptom-
atic people require or will benefit from EBCT. Additional
appropriately designed studies of EBCT for this purpose are
strongly encouraged. In the setting of this degree of uncer-
tainty, EBCT screening should not be made available to the
general public without a physician’s request.
The usefulness of EBCT in determination of changing
calcium scores that correlate with regression or progression
of CHD is currently being studied intensively. However, the
test-to-test variability and the interrater reliability of the
calcium score measurement in the same individual studied at
close intervals in time have been deterrents to the recommen-
dation of serial EBCT scans for determining the response of
coronary artery stenosis lesions to medical interventions
designed to cause regression of disease. The Writing Group
concluded that this is a promising use of EBCT, but the small
number of published studies require corroboration before
EBCT can be widely recommended for this purpose.
Our conclusions are consistent with the recommendation of
the Agency for Health Care Policy and Research–funded
BC/BS TEC, the Prevention V Conference report of the AHA
(Dr Philip Greenland), and the MESA project currently being
planned by the NIH/NHLBI. The latter study will evaluate
EBCT and other techniques in the long-term assessment of
CHD risk in 6500 apparently healthy people. As additional
data are obtained, our conclusion might require revision.
This Writing Group encourages further properly designed
outcomes research using EBCT and additional studies of the
role of EBCT and patient follow-up for assessing progression
or regression of CHD.
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I. Preamble
The present document is an Expert Consensus Document that
includes evidence about the use of EBCT for the detection of
calcium as a marker of coronary atherosclerosis. This type of
document is intended to inform practitioners, payers, and
other interested parties of the opinion of the ACC, often in
collaboration with the AHA, concerning evolving areas of
clinical practice and/or technologies that are widely available
or new to the practice community. Topics chosen for cover-
age by Expert Consensus Documents are so designed because
the evidence base and experience with technology or clinical
practice are not considered sufficiently well developed to be
evaluated by the formal ACC/AHA Practice Guidelines
process. Often, as in this case, the topic is the subject of
considerable ongoing investigation. Thus, the reader should
view the Expert Consensus Document as the best attempt of
the ACC and AHA to inform and guide clinical practice in
areas where rigorous evidence may not yet be available or the
evidence to date is not widely accepted. Where feasible,
Expert Consensus Documents will include indications or
contraindications. Some topics covered by Expert Consensus
Documents will be addressed subsequently by the ACC/AHA
Practice Guidelines Committee.
II. Consensus Statement Method
The ACC has not previously provided a scientific statement
or a consensus document relative to the use of EBCT. At its
first meeting, each member of this ACC/AHA Writing Group
indicated in writing any relationship to advisory committees,
speakers’ bureaus, or stock holdings that could be perceived
as a conflict of interest; no relevant conflicts of interest were
reported. The first step in the development of this document
was to obtain a complete literature review from the Griffith
Resource Library at the ACC concerning EBCT from 1995 to
1998 (National Library of Medicine’s Elhill System). Addi-
tional relevant prior or subsequently published references
have also been identified, as well as manuscripts currently in
press. At the first meeting, various members of the Writing
Group were asked to provide a description and analysis of
EBCT for identifying coronary risk in the asymptomatic
patient, for determining the likelihood of obstructive CAD in
symptomatic patients, and for detecting the progression or
regression of coronary atherosclerotic lesions in patients with
known CHD. Each individual contributor to these parts of the
document had his or her initial written presentation critiqued
by 1 or 2 additional members of this Writing Group. Addi-
tional members of the Writing Group provided text concern-
ing the accuracy of the test, alternative approaches to the
detection of obstructive CAD, and the economic impact of
developing new technology in this era of constrained
resources.
During the time when this document was being developed,
a discussion of EBCT and CHD risk prediction in the
asymptomatic individual (atherosclerotic burden) was held at
the Prevention V Conference of the AHA in San Francisco,
Calif, on October 28, 1998. It was cochaired by 2 members of
this Writing Group (Drs Philip Greenland and Scott Grundy).
A third member of this Writing Group (Dr Victor Froelicher)
participated in Writing Group III at the AHA Prevention
Conference.
The BC/BS TEC, with a large research staff and one of the
AHCPR evidence-based practice centers, provides technol-
ogy assessment services to BC/BS member plans, managed
care plans, and others. They do not directly recommend
reimbursement or nonreimbursement. They recently assessed
the EBCT detection of coronary artery calcium, including its
cost-effectiveness, and presented their results to the BC/BS
Medical Advisory Board on December 10, 1998, at a meeting
attended by the Chair of this Writing Group (Dr O’Rourke).
In discussions with ACC leadership, the BC/BS Advisory
Panel TEC indicated their willingness to make the results of
their assessment on EBCT available to this Writing Group.
The BC/BS “TEC Assessment of Diagnosis and Screening
for Coronary Artery Disease With Electron Beam Computed
Tomography” has recently been completed.*
Also relevant to this report is the initiation of the MESA
project by the NHLBI. The MESA protocol, which is in its
design phase, will assess the relationship between baseline
risk factors and other possible indicators of subclinical
disease and future clinical outcomes. There will be a 10-year
follow-up, and coronary artery calcium will be evaluated by
either EBCT or helical computed tomography (CT) to deter-
mine its utility in risk stratification.
III. Principles of Technology Assessment
The development of new medical technology has been a
major factor contributing not only to the improved health of
the American public, but also to the rising cost of health care
(5). On the basis of current estimates, as much as one third to
one half of the higher real expenditures for health care are due
to an increase in the volume and intensity of services that
include the use of new technology (5–7). Of course, this
technology has been invaluable for many patients.
During the past 2 decades, a number of innovative tech-
niques have been introduced within diagnostic cardiology
that have resulted in improved test performance (ie, sensitiv-
ity) for the detection of obstructive CAD. Improvements in
test accuracy in the area of diagnostic cardiology have been
uniformly associated with higher test costs. Historically, as
new technology was developed, it was expected that users
would pay for newer, more high-tech imaging tests without
any justification of the incremental cost of the new technol-
ogy. The resulting economic pressures placed on physicians
in the current era of healthcare reform are forcing a rethinking
of the medical applications of a number of testing modalities.
The evaluation of CHD can utilize many testing modalities.
The Writing Group accepted the principle that the future of
any new technology must now undergo a rigorous evaluation
before routine use and application in daily clinical decision
making. The limited diffusion of new technologies (eg,
EBCT and contrast-enhanced echocardiography) in today’s
healthcare market indicates that clinicians and healthcare
administrators are making more cautious choices about new
*Blue Cross/Blue Shield Association (1999). Diagnosis and screening
for coronary artery disease with electron beam computed tomography.
TEC Assessment Program, 13 No. 27. March 1999.
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technology by awaiting a greater compendium of results
applied throughout a wide variety of patient subsets. Al-
though a new test may be less expensive than others previ-
ously available, in some cases, tests with low specificity may
result in add-on tests that lead to additional costs without
improving patient outcomes.
Although not every decision in clinical medicine will be
supported by randomized trials, broader evidence for the use
of EBCT is needed. Promising tests or therapies that seem
intuitively attractive have often not proved to be effective
when evidence was required (eg, systolic time intervals,
digital subtraction left cineangiography, and aortic
valvuloplasty).
In estimating the accuracy of a noninvasive test for
obstructive CAD, there are methodological limitations that
hinder our understanding of true predictive accuracy. In
general, positive results are more likely to be published,
reflecting publication bias, with an overestimation of test
accuracy.
Another common problem that often occurs early in the
evaluation of a new imaging modality is that of limited
challenge. Limited challenge is present in studies that com-
pare test results from diseased and normal populations (ex-
treme ends of the disease-prevalence continuum). In general,
it is the goal of this type of analysis for the abnormal test
results to occur in diseased patients and for normal test results
to occur in patients without obstructive disease. Because the
patient populations are extremely skewed, the results overes-
timate test accuracy.
The most notable limitation to assessing diagnostic accu-
racy is the calculation of test sensitivity and specificity. The
patients who proceed to diagnostic cardiac catheterization
define this calculation. In general, a predominant number of
patients who proceed to cardiac catheterization are those with
abnormal test results, reflecting the routine workup for
suspected obstructive CAD (workup or verification bias). As
a result of a greater number of patients with abnormal test
results being referred to the “gold standard” of coronary
angiography, test sensitivity is enhanced. Conversely, those
patients with normal test results who are referred to arteriog-
raphy include patients with high-risk clinical history of
symptoms and those with other myocardial or valvular heart
disease. Thus, test specificity is lowered and poorly reflects
the exclusion of disease in patients with normal or low-risk
test results.
The failure to eliminate workup bias has been a problem
with most of the studies evaluating the diagnostic character-
istics of a noninvasive test for the detection of obstructive
CAD. Normal clinical practice results in certain patients
being selected or referred for a test (referral bias), with only
certain patients being selected for further evaluation (posttest
bias). For instance, after an exercise test, cardiac catheteriza-
tion would be chosen particularly for those with a low
exercise capacity and/or abnormal ST response. Most of the
studies that have evaluated the characteristics of tests for
CAD, using the appropriate gold standard of cardiac cathe-
terization, have some degree of workup bias.
An important third consideration is the importance of the
end points chosen when data other than the coronary arterio-
gram are used. Hard end points are myocardial infarction and
death, whereas soft end points include chest pain and coro-
nary interventions. Screening studies provide the best exam-
ple of the problem with using soft end points instead of hard
end points. When angina is included as an end point,
nonspecific symptoms in a subject with an abnormal test
result are more likely to be called CAD during the follow-up
period. Hard end points, like death or myocardial infarction,
eliminate this misclassification and are more appropriate.
There is a definite problem with the use of interventions as
cardiac end points. With modern treatment, there often are
inadequate numbers of cardiovascular deaths and infarctions
in most populations studied to obtain statistically significant
results. Therefore, to have enough end points, follow-up
studies have often included bypass surgery or percutaneous
coronary artery interventions as end points. In fact, very often
the majority of the end points are interventions. This is
problematic, because the test result often determines who
undergoes these procedures, and it is invalid to include them
as events predicted by the test.
In screening studies, the populations should truly be
asymptomatic and should represent a random or systemati-
cally selected sample of the target population. Volunteers are
not appropriate, because they usually represent the extremes
of the population: the most healthy and those who are
concerned for personal reasons regarding their health (eg,
family history or symptoms they chose to deny). Volunteers
represent a subtle form of limited challenge by introducing
the extremes into the data set.
A problematic surrogate is the use of other test results such
as nuclear imaging instead of angiography as a gold standard.
It is well known that nuclear imaging has limitations in
predicting obstructive CAD and cannot be used to replace the
best standard available. Surrogates for standards should be
considered carefully and justified only when they perform
equal to or better than the standard itself.
Screening can be defined as the presumptive identification
of unrecognized disease by the use of procedures that can be
applied rapidly. The relative value of techniques for identi-
fying individuals who have asymptomatic or latent obstruc-
tive CAD should be assessed to optimally and cost-
effectively direct secondary preventive efforts toward those
with disease.
Eight criteria have been proposed for the selection of a
screening procedure:
1. The procedure is acceptable and appropriate.
2. The quantity and/or quality of life can be favorably
altered.
3. The results of intervention outweigh any adverse
effects.
4. The target disease has an asymptomatic period during
which its outcome can be altered.
5. Acceptable treatments are available.
6. The prevalence and seriousness of the disease justify the
costs of intervention.
7. The procedure is relatively easy and inexpensive.
8. Sufficient resources are available.
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In addition, 7 guidelines have been recommended for
deciding whether a community screening program does more
harm than good:
1. Has the program’s effectiveness been demonstrated in a
randomized trial, and if so,
2. Are efficacious treatments available?
3. Does the current burden of suffering warrant screening?
4. Is there a good screening test?
5. Does the program reach those who could benefit from
it?
6. Can the healthcare system cope with the screening
program?
7. Will those who had a positive screening comply with
subsequent advice and interventions?
The demonstration of the effectiveness of a screening
technique requires the randomization of the target population,
with half receiving the screening technique; standardized
action taken in response to the screening test results; and then
outcomes assessment. For the screening technique to be
effective, the screening group must have lower mortality
and/or morbidity. Such a study has been completed for
mammography but not for any cardiac testing modalities. The
next best validation of efficacy is to demonstrate that the
technique improves the determination of those asymptomatic
individuals with higher risk for events over that possible with
the available risk factors. Mathematical modeling makes it
possible to determine how well a population will be classified
if the characteristics of the testing methods are known.
IV. Introduction to EBCT Consensus Report
Coronary arterial calcification is part of the development of
atherosclerosis, occurs exclusively in atherosclerotic arteries,
and is absent in the normal vessel wall (8–10). Coronary
artery calcification occurs in small amounts in the early
lesions of atherosclerosis that appear in the second and third
decades of life; it is found more frequently in advanced
lesions and in older age. Although there is a positive
correlation between the site and the amount of coronary
artery calcium and the percent of coronary luminal narrowing
at the same anatomic site, the relation is nonlinear and has
large confidence limits (11). The relation of arterial calcifi-
cation, like that of angiographic coronary artery stenosis, to
the probability of plaque rupture is unknown (12,13). Vul-
nerable plaque is frequently present in the absence of calci-
fication (14). Although EBCT and helical CT have been very
sensitive in defining coronary artery calcium and may pro-
vide a measure of total coronary plaque burden, calcium does
not concentrate exclusively at sites with severe coronary
artery stenosis (15).
EBCT, the subject of this document, uses an electron gun
and a stationary tungsten “target” rather than a standard x-ray
tube to generate x-rays, thus permitting very rapid scanning
times. EBCT serial transaxial images are obtained in 100 ms
with a scan slice thickness of 3 to 6 mm for the purpose of
detecting coronary calcium. Thirty to 40 adjacent axial scans
usually are obtained. The scans usually are obtained during 1
or 2 breath-holding sequences and are triggered by the ECG
signal at 80% of the R-R interval, near end diastole before
atrial contraction, thus minimizing the effect of cardiac
motion. The rapid image-acquisition time virtually eliminates
motion artifact related to cardiac contraction. Thus, specific
epicardial coronary arteries are easily visualized by EBCT
because the lower CT density of periarterial fat markedly
contrasts to blood in the coronary arteries, whereas the mural
calcium is identified because of its high CT density relative to
soft tissue and blood (16). Also, the scanner software allows
quantification of calcium area and density. A calcium scoring
system has been devised based on the x-ray attenuation
coefficient, or CT number measured in Hounsfield units, and
the area of calcium deposits (17). A study for coronary
calcium is completed within 10 to 15 minutes, requiring only
a few seconds of scanning time.
EBCT has been used with increasing frequency in the
United States and other countries during the past 10 years in
screening asymptomatic individuals for the purpose of iden-
tifying those at high risk for developing clinical signs and
symptoms due to obstructive CHD. More recently, EBCT has
been used to identify the likelihood of CHD in patients who
present with nondiagnostic chest pain. Currently, EBCT is
being studied for the assessment of progression or regression
of coronary artery lesions after interventions in patients with
modifiable risk factors for CHD (18). There have been
considerable data published in various medical journals
supporting the usefulness of EBCT for detecting the presence
and density of calcium in atherosclerotic coronary arteries.
A writing group of the AHA developed a scientific
statement for health professionals in 1996 (15) that concluded
that there was no role at that time for the use of EBCT for
screening populations of young, healthy individuals with no
risk factors and that the importance of calcification in such
individuals was inconclusive.
This Writing Group agrees with the following points
indicated in that scientific statement:
1. A negative EBCT test makes the presence of athero-
sclerotic plaque, including unstable plaque, very
unlikely.
2. A negative test is highly unlikely in the presence of
significant luminal obstructive disease.
3. Negative tests occur in the majority of patients who
have angiographically normal coronary arteries.
4. A negative test may be consistent with a low risk of a
cardiovascular event in the next 2 to 5 years.
5. A positive EBCT confirms the presence of a coronary
atherosclerotic plaque.
6. The greater the amount of calcium, the greater the
likelihood of occlusive CAD, but there is not a 1-to-1
relationship, and findings may not be site specific.
7. The total amount of calcium correlates best with the
total amount of atherosclerotic plaque, although the true
“plaque burden” is underestimated.
8. A high calcium score may be consistent with moderate
to high risk of a cardiovascular event within the next 2
to 5 years.
V. Risk Assessment for CHD in
Asymptomatic Populations
Possibly as many as half of first coronary events (including
sudden cardiac death) occur in asymptomatic people. There-
fore, screening for both clinically silent CHD and the risk of
developing clinical CHD represents 2 major health chal-
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lenges. Lipid-lowering drug trials in asymptomatic people
(19), including those with hypercholesterolemia and with
relatively unremarkable lipid levels (20), have revealed the
potential for risk reduction of CHD events in primary
prevention. Thus, the potential exists for many asymptomatic
people to benefit from identification and risk reduction in the
asymptomatic phase of CHD. A screening modality that
properly classifies at-risk asymptomatic individuals could be
extremely valuable in prevention of CHD. The AHA Preven-
tion V Conference was designed to consider the opportunities
that might currently exist to improve risk stratification among
asymptomatic people. EBCT was considered at the Preven-
tion V Conference along with several other tests, such as
carotid ultrasound, ankle-brachial index, and MRI. The full
Prevention V Conference report is available elsewhere (21).
Major risk factors including cigarette smoking, hyperten-
sion, elevated low-density lipoprotein (LDL) cholesterol, low
HDL cholesterol, diabetes mellitus, and advancing age are
clearly related to extent of coronary atherosclerosis and to the
risk of clinical CHD events. All except advancing age are
believed to be direct causes of coronary atherosclerosis (22).
Variations in plaque burden and risk are most likely due to
genetic susceptibility and other factors, such as risk factor
combinations, duration of risk factor exposures, and biolog-
ical and laboratory variability. As mentioned, EBCT is one of
several measures of subclinical coronary atherosclerosis that
are under consideration for improving the process of risk
assessment in asymptomatic people. It has been advanced by
some that the calcium score may become a surrogate for age
in the determination of individuals who are at high risk for
coronary events (22).
EBCT is a sensitive means of detecting coronary calcium
(11). Histological studies support the association of tissue
densities $130 HU with calcified arterial plaque (23). How-
ever, noncalcified plaque and lipid-laden “vulnerable” plaque
can be present in the absence of EBCT calcium (15). High
calcium scores increase the probability of vulnerable plaques
but do not identify specific vulnerable lesions (15).
Calcium accumulates in coronary arteries in an age-related
manner, and the accumulation appears to be exponential,
because calcium continually deposits in preexisting lesions;
thus, all scores must be adjusted for age, as well as for sex. As
an example, a calcium score of 100, which is sometimes used
as a standard for high risk, is at the 50th percentile for
individuals 60 years of age and at the 25th percentile for those
who are 50 years old.
The presence and extent of coronary calcium appear
closely related to overall atherosclerotic coronary plaque
“burden”; however, there are few reports of long-term
follow-up in asymptomatic populations linking coronary
calcium scores with risk of subsequent coronary events
(Table 1). The individuals studied by Secci et al (4) represent
a subgroup of the larger study by Detrano et al (2). For the
purpose of this document, we focused our attention on the
estimation of hard coronary events, including cardiac death or
nonfatal myocardial infarction, as well as other combined
event estimation. The use of combined-event analysis, includ-
ing coronary revascularization procedures, remains contro-
versial, because test results per se may influence the treatment
decision. However, revascularization that occurs remote from
the test result is reflective of failed medical therapy and
unrelated to EBCT test results. We present both hard coro-
nary event and combined-event models in this review. In
addition, we attempted to collect follow-up data that were
analyzed by risk-adjusted methods and/or stratified analysis
that included important cardiac risk factors. There are a total
of 4 published articles on the subject of risk estimation with
coronary calcium scores (2–4,24).
Unadjusted Estimation of Outcome
In the published series by Arad et al (3), 1173 asymptomatic
subjects underwent EBCT in the years 1993 to 1994, with an
average follow-up of 19 months; in that period, 1 death and 7
nonfatal myocardial infarctions were documented. From that
preliminary report, unadjusted comparisons of events re-
vealed a significant association between coronary calcium
and major coronary events (unadjusted odds ratios [OR] 20.0
to 35.4). Additional follow-up of 3.6 years and 18 cardiac
events revealed a similar association of coronary calcium
with cardiac death or myocardial infarction (25). In a subset
analysis of women and men, the positive predictive values
were 11.0% and 18.0% and the negative predictive values
were 99.3% and 99.1%, respectively. In a smaller series by
Secci and colleagues (4), 326 patients with $1 risk factor
were followed up for 32 months with a 50% prevalence of
coronary calcium scores .156. Half of all hard cardiac events
TABLE 1. Risk Stratification With Measures Derived From EBCT
Study n Entry Criteria Event Definition
%
Follow-Up
Mean
Follow-Up,
y
Annualized
Event Rate, %
Calcium
Definition
CAC
Prevalence, %
Arad et al, 1996 (3) 1173 Asymptomatic, prior CAD or
angina
Cardiac death, MI,
thromboembolic stroke,
revascularization
99.8 1.6 1.5 Score $100 11.8
Secci et al, 1997 (4)* 326 Asymptomatic $1 risk
factor, no prior MI or
angina
Death, MI 90 2.7 1.5 Score .156 50.0
Detrano et al, 1999 (2) 1196 Asymptomatic with multiple
risk factors, no prior MI or
angina
Death, MI 99 3.4 1.6 Score .0
(median544)
68
n indicates number of individuals studied; CAC, coronary artery calcium; and MI, myocardial infarction.
*A subgroup of a larger report by Detrano et al.
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occurred for patients with the highest-quartile 3-mm-scan
coronary calcium score. In a pooled analysis, there appears to
be an association with coronary calcium scores and cardiac
events (Figure 1). With coronary calcium scores of ,15, 100,
156 to 160, and 507 to 680, the positive predictive value
increased from 1.5% to 4.8%, 6.4%, and 14%, respectively
(Figure 1). The negative predictive values for the same
coronary calcium scores were 98.5%, 97.9%, 95.9%, and
92.2%, respectively. Pooled and weighted-average (weighted
by the sample size) predictive accuracies were 0.71 and 0.47.
When coronary calcium score thresholds ranging from 75 to
150 were used, the summary relative risk was increased
23.7-fold with a 95% confidence interval (CI) from 0.711 to
101.2 (P.0.20). Similarly, when a combined end point of
mortality plus all associated cardiovascular complications
was used, Arad et al (3) reported a 61-fold higher OR in
asymptomatic patients when a calcium score $100 was
observed. By comparison, the OR was not elevated for their
risk of death or myocardial infarction (OR 2.0, 95% CI 0.5 to
8.2, P.0.20).
Risk-Adjusted Estimation of Outcome
When outcome is evaluated, it is critical to consider the added
value of test information after all of the information available
to the clinician before EBCT referral has been weighed. This
may be documented by examining risk-adjusted outcomes
that control for established cardiac risk factors (eg, age and
cholesterol levels). There have been several reports that have
attempted to evaluate the incremental predictive value of the
EBCT coronary calcium score in consideration with other
cardiac risk factors. In general, because these data are still
early in development, the small sample sizes and limited
follow-up impair the statistical power in this outcome assess-
ment. The most common method of evaluating outcomes in
small samples of patients undergoing noninvasive testing is to
use combined end points. In addition to the hard end points of
death or myocardial infarction, other outcomes, including
revascularization, are frequently used. Because revasculariza-
tion is often precipitated by information derived from the test,
the analysis is biased toward finding a significant association.
Despite this limitation, we culled the preliminary data to
estimate differences in outcome using hard and combined end
points, because a proportion of the coronary revasculariza-
tions would be expected to occur remotely from the test and
as a result of failed medical therapy.
A risk-adjusted logistic regression model estimating coro-
nary events was performed in the Secci series (4). When
controlling for sex, age, diabetes mellitus, ECG left ventric-
ular hypertrophy, smoking, hypertension, family history of
disease, and cholesterol levels, the log of the coronary
calcium score was not a significant estimator of cardiac death
or myocardial infarction (risk-adjusted OR 1.24, 95% CI 0.49
to 3.11). When risk of death, myocardial infarction, or
revascularization was estimated, the calcium score was an
independent estimator of patient outcome (including referral
to coronary surgical procedures), with a risk-adjusted OR of
2.87 (95% CI 1.04 to 7.94). Conversely, Detrano et al (24)
reported application of stepwise logistic regression analysis
in 491 symptomatic patients who were referred to coronary
angiography (86% follow-up of patients). In that referral
population, when controlling for established cardiac risk
factors, the log of the calcium score was an independent
estimator of combined cardiac events (including death or
myocardial infarction). In a second report from the South Bay
Heart Watch program (2), the prognostic value of EBCT was
evaluated in 1196 asymptomatic, high-coronary-risk subjects
(mean follow-up of 41 months). The overall rate of cardiac
death or myocardial infarction was 3.8% with a median
coronary calcium score of 44. Multivariable models estimat-
ing coronary risk without and with the calcium scores
revealed a similar ability to classify infarction or death
(receiver operator characteristic [ROC] curve area without
coronary calcium50.68, ROC curve area with coronary
calcium50.71, P50.09). The authors concluded that neither
cardiac risk factor assessment nor EBCT was able to provide
an adequate prediction of events in these generally high-risk
subjects.
In the Secci study (4) of a subgroup of the patients included
in the 1999 report by Detrano et al (2), 6-mm-scan and
3-mm-scan protocols were compared in 326 patients; the 2
protocols were found to be equal in their predictive accuracy
for cardiac events. Using pooled analysis of coronary calcium
scores alone from the Arad (3) and Secci series (4) of ,15,
100, 156 to 160, and 507 to 680, the positive predictive value
increased from 1.2% to 5.5%, 6.6%, and 14%, respectively
(Figure 1). The coronary events that went undetected by the
higher threshold included many soft events, as did the entire
group. One additional report appearing in abstract form is
also worthy of mention (26). Of a total of 367 self-referred
middle-aged women and men followed up for 3 to 6 years, the
OR for nonfatal myocardial infarction or cardiac death was
22 times greater for patients with the highest tertile of calcium
scores than for those with scores in the lowest tertile. The
increasing predictive values in these studies were associated
with the calcium scores alone and were not compared with
other methods of assessing risk.
In summary, review of the small number of reports in the
literature reveals that EBCT calcium score can predict CAD
risk. Current data, however, include relatively small samples
(fewer than 3000 asymptomatic subjects) with rare occur-
rences of hard coronary events (death or myocardial infarc-
Figure 1. Positive and negative predictive value of EBCT coro-
nary calcium scores from the Arad (3) and Secci (4) series
(unadjusted for other risk factors).
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tion). Prediction of all types of hard CAD events has not been
demonstrated in patient samples. Importantly, the incremental
value of EBCT over “traditional” multivariate risk-
assessment models has not yet been established (2).
Although preliminary data are intriguing with respect to
risk prediction in the asymptomatic patient, available data are
insufficient to support recommending EBCT to asymptomatic
members of the general public or for routine clinical use.
Further studies are enthusiastically recommended for deter-
mining the additive predictive effect of the calcium score in
patients with intermediate risk, particularly in the elderly. The
use of EBCT in selected asymptomatic patients can be
justified when performed in the context of a medical assess-
ment only after the more standard cardiac risk assessment is
considered insufficient by the physician to direct further
therapy plans.
Comparative Modalities for Risk Assessment
The diagnostic accuracy of other comparative modalities has
been explored in a number of prior reports (27–31). Although
the predictive value of testing has been limited in asymptom-
atic patient groups, high-risk subsets have been identified
when information from risk factors and tests is combined. For
example, when testing was performed in patients with mul-
tiple risk factors, a markedly abnormal ECG exercise test was
associated with a significant increase in cardiac event risk
(31). When risk in asymptomatic patients was evaluated with
combined test information, the presence of abnormalities on
both the exercise ECG and myocardial perfusion study
increased the OR from 3.6- to 14.5-fold for the development
of future clinical coronary disease (48% had cardiac events
over a 4-year period) (31). Similarly, the positive predictive
value of exercise myocardial perfusion imaging in asymp-
tomatic patients with an abnormal exercise ECG for obstruc-
tive CAD is 74% (27,28). Targeting treatment to high-risk
patients with noninvasive tests should lead to important
alterations in outcome. The long-term benefit of treatment of
patients with abnormal ECGs was recently reported from
MRFIT (Multiple Risk Factor Intervention Trial; 11 880
subjects) (29). After adjustment for baseline clinical risk, the
aggressive risk factor–reduction program in the special-
intervention group resulted in a 61% reduction in the relative
risk of death due to CHD in men with a positive test (defined
by use of the exercise ECG ST/HR index) compared with
those in the usual-care group (29). Whether or not EBCT will
detect more patients at high risk remains to be proven.
The AHA Prevention V Conference considered several
other alternative tests for assessment of coronary risk in
asymptomatic people. The ankle-brachial blood pressure
index and B-mode carotid Doppler ultrasound assessment of
intimal-medial thickness, for example, have both been dem-
onstrated to add substantial incremental value in risk predic-
tion over and above traditional Framingham-type risk score,
TABLE 2. Coronary Disease and Calcium Prevalence in Patients Undergoing EBCT and Cardiac Catheterization
Study
Study
Patients,
n Entry Criteria CAD Definition
CAD
Prevalence,
% Calcium Definition
CAC
Prevalence,
%
Tanenbaum et al, 1989 (11) 54 $70% 79.6 Detectable calcium 70.4
Agatston et al, 1990 (17) 584 $50% or prior MI 18.7 Score .0 77.1
Breen et al, 1992 (33) 100 $50% 47.0 Score .0 75.0
Bielak et al, 1994 (34) 160 $50% 48.8 Hyperattenuating foci .2 mm2 50.0
Kaufmann et al, 1995 (35) 160 Age ,60 y,
no prior CAD or
transplant history
$50% 69.4 Detectable calcium 60.6
Devries et al, 1995 (36) 140 $70% 70.0 Score .1 75.0
Kajinami et al, 1993 (37) 251 $75% 53.0 Score .0 55.0
Rumberger et al, 1995 (38) 139 Age ,60 y,
no prior CAD or
transplant history
$50% 46.8 Detectable calcium 78.4
Braun et al, 1996 (39) 102 .50% 78.4 Detectable calcium 78.4
Budoff et al, 1996 (40) 710 .50% 60.1 Detectable calcium 79.3
Detrano et al, 1996 (24) 491 $50% 43.0 Score .100 43.0
Fallavollita et al, 1994 (41) 98 ,50% Stenosis Luminal irregularities 60.2 Score $5 40.8
Baumgart et al, 1997 (42) 57 $50% 51.0 Score .0 42.1
Schmermund et al, 1997 (43) 118 Acute ischemic syndromes .50% 93.2 Score .0 89.8
Kennedy et al, 1998 (44) 368 .50% 42.9 Detectable calcium 81.0
Schmermund et al, 1998 (32) 49 ,20% Stenosis Vessel wall irregularities/
increased lumen caliber
53.1 Spotty coronary calcium 57.1
Pooled estimates 3683 48.8 74.9
Median 140 56.6 75.0
Average 224 60.0 68.3
CAC indicates coronary artery calcium.
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particularly in persons aged 55 years and older. None of these
tests have been compared directly to EBCT in any study for
coronary event prediction. The NHLBI MESA study is
intended to determine which comparative measures are addi-
tive to traditional coronary risk factor models.
VI. Diagnosis of Patients With Possible CHD
by EBCT
EBCT can be used as a noninvasive diagnostic technique for
detecting obstructive CAD. To define its test characteristics
and to compare it with other noninvasive tests, a meta-anal-
ysis was performed by our Writing Group.
Methods
MEDLINE searching strategies with the keyword “electron
beam computed tomography” were used. Each abstract was
reviewed online for study content including the diagnostic or
prognostic accuracy of coronary calcium scores determined
by EBCT. Entry criteria were limited to reports on the use of
EBCT to assess the diagnostic or prognostic accuracy of
coronary artery calcium. Workup bias (verification bias)
could not be excluded in all cases. Investigators were queried
as to patient overlap, and 2 reports were excluded. Data
collection included documentation of a 232 frequency table
of significant coronary disease by coronary artery calcium
score thresholds with the best threshold as identified in each
report. Individual study determination of significant coronary
disease and calcium score cut points varied by study and are
detailed in Table 2. For diagnostic accuracy, the sensitivity
(true-positives/[true-positives plus false-negatives]) and spec-
ificity (true-negatives/[true-negatives plus false-positives]) of
coronary calcium scores were calculated. Average, median,
and weighted-average (proportional to the sample size) scores
were calculated. ORs and 95% CIs were calculated with
FASTPRO software. Meta-analysis included calculation of a
summary OR (95% CI) by use of a random-effects model (ie,
empirical Bayes method). A x2 test for homogeneity was used
to examine the combinability of the studies. For a test for
homogeneity, a value of P.0.05 indicates that the studies
may be combined in the form of a summary measure
(df5number of studies21).
Figure 2. Summary ROC curve (95% CI) of diagnostic accuracy
data in EBCT revealing a high test sensitivity (ie, true-positive
rate) achieved at a high false-positive rate.
TABLE 3. Diagnostic Accuracy of EBCT in Catheterized Patients
Study True 2 True 1 False 2 False 1
Sensitivity,
%
Specificity,
%
Predictive
Accuracy, % OR LCI UCI
Tanenbaum et al, 1989
(11)
11 38 5 0 88.4 100.0 90.7 148.7 9.6 2314.0
Agatston et al, 1990 (17) 134 105 0 345 100.0 28.0 40.9 72.6 5.8 910.9
Breen et al, 1992 (33) 25 47 0 28 100.0 47.2 72.0 32.9 2.4 453.8
Bielak et al, 1994 (34) 68 66 14 12 82.5 85.0 83.8 26.7 11.5 62.0
Kaufmann et al, 1995 (35) 42 90 7 21 92.8 66.7 82.5 25.7 10.1 65.1
Devries et al, 1995 (36) 33 58 2 47 96.7 41.3 65.0 20.2 4.6 87.3
Kajinami et al, 1993 (37) 106 121 12 12 91.0 90.0 90.4 101.6 43.9 235.1
Rumberger et al, 1995 (38) 29 176 1 45 99.4 25.7 81.7 39.8 5.6 284.3
Braun et al, 1996 (39) 16 74 6 6 92.5 72.7 88.2 32.8 9.4 114.9
Budoff et al, 1996 (40) 124 404 23 159 94.6 43.8 74.4 13.7 8.5 22.2
Detrano et al, 1996 (24) 200 148 80 63 70.0 71.0 70.9 5.9 4.0 8.7
Fallavollita et al, 1994 (41) 34 35 5 24 87.5 58.6 70.4 9.9 3.4 28.9
Baumgart et al, 1997 (42) 6 18 1 22 94.7 21.4 51.1 63.6 7.4 545.2
Schmermund et al, 1997
(43)
7 105 1 5 99.1 58.3 94.9 141.6 15.3 1308.0
Kennedy et al, 1998 (44) 64 151 7 146 95.6 30.5 58.4 9.5 4.19 21.3
Schmermund et al, 1998
(32)
14 19 9 7 67.9 66.7 67.3 4.2 1.27 14.1
Pooled statistics 913 1655 173 942 90.5 49.2 69.6 212.3 4.3 105.8
Median 93.7 58.5 78.1 72.8 8.5 114.9
Average 91.8 55.0 77.0 52.9 11.8 367.0
Weighted average 80.4 39.9 59.1 21.3 4.3 105.7
True 2, no disease in a negative test; True 1, disease in a positive test; False 2, disease in a negative test; False 1, no disease in a positive test; LCI, lower
95% CI; and UCI, upper 95% CI.
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Results
A total of 3683 patients were enrolled in 16 studies evaluating
the diagnostic accuracy of EBCT (Table 2). Inclusion criteria
were diagnostic catheterization for patients without prior
history of coronary disease or prior cardiac transplantation.
Two reports (24,32) included only patients with nonobstruc-
tive coronary disease as defined by a stenosis ,50% or
,20%. On average, significant coronary disease was reported
in 57.2% of the patients. Significant luminal stenosis was
defined as luminal irregularities in 2 reports, .50% or $50%
stenosis in 11 reports, and $70% or $75% stenosis in 3
reports. Definitions of the optimal coronary artery calcium
score for each report included detectable calcium (n58),
scores .0 to 5 (n57), and scores .100 (n51). Significant
coronary artery calcium was reported on average in 65.8% of
patients (Table 2).
Additional Summary ORs
Varying stenotic lesion cut points: minimal stenosis56.78
(2.95 to 15.58); .50% stenosis516.42 (5.08 to 53.07);
.70% stenosis549.83 (24.11 to 103.0).
Varying stenotic lesion cut points: detectable calcium or
score $5 525.61 (9.6 to 68.37); score $10055.87 (3.97 to
8.7) including only the Detrano series (2).
x2 Test for homogeneity for all studies563.31, df515,
P,0.0001.
Test for homogeneity for diagnostic catheterization pa-
tients556.26, df512, P,0.0001.
x2 Test for homogeneity for diagnostic catheterization
patients with detectable calcium or score cut point of 0, 1, or
5516.25, df59, P50.62.
x2 Test for homogeneity for diagnostic catheterization
patients with nonobstructive disease51.08, df51, P50.30.
Table 3 depicts the frequency of published EBCT data and
pooled accuracy estimates from 16 reports (n53683). The
weighted-average (by sample size) sensitivity and specificity
were 80.4% and 39.9%, respectively. This may be compared
with the pooled sensitivity and specificity values of 90.5%
and 49.2%, respectively. Individual study sensitivity values
ranged from 68% to 100%, whereas specificity values ranged
from 21% to 100%. Calculation of a summary ROC curve
(Figure 2) revealed that high-sensitivity values were consis-
tently associated with exceedingly high false-positive rates.
Predictive accuracy (ie, percent correct classification) ranged
from 41% to 95% (weighted average559%, pooled
value570%).
The weighted-average or summary odds were elevated
20-fold with an abnormal coronary calcium score (95% CI
4.6 to 87.8). Additional summary ORs were also calculated
with various anatomic and calcium score cut points. For
detection of minimal, .50%, and .70% stenosis at cardiac
catheterization, the summary odds increased from 6.8-fold
(95% CI 3 to 15.6) to 16.4-fold (95% CI 5.1 to 53.1) to
50-fold (95% CI 24.1 to 103.0); that is, the odds of significant
coronary disease increased when greater angiographic lesion
thresholds were used for significant disease (although the
confidence bounds widened). Significant coronary calcium
scores had a higher accuracy in detecting disease with
stenosis .50%. Higher coronary calcium scores increased the
likelihood of detecting significant coronary disease. A thresh-
old of detectable calcium or a score $5 was associated with
an odds of significant disease of 25.6-fold (95% CI 9.6 to
68.4). From the Detrano series (2), the odds of significant
disease for a score $100 was 5.9-fold higher (95% CI 4 to
8.7). Of note is the significant heterogeneity statistic for the
16 studies (P,0.0001), indicating populations too diverse to
provide meaningful summary estimates. The diversity is due
to the use of various coronary calcium score thresholds,
patient entry criteria, and angiographic disease thresholds. A
nonsignificant homogeneity statistic was noted when studies
used minimal calcium score thresholds (detectable calcium or
score of 0, 1, or 5 [P50.62]). Similarly, the 2 reports (2,3)
were similar for patients with nonobstructive disease estimat-
ing minimal coronary stenosis (P50.30). These results indi-
cate extreme heterogeneity across the study results, and the
summary statistics should then be viewed as representing
divergent patient samples.
Using a different approach, Schmermund and associates
(45) recently examined 291 patients with suspected CHD
who underwent risk factor determination as defined by the
National Cholesterol Education Program, EBCT, and clini-
cally indicated coronary angiography. On the basis of a
simple algorithm (“noninvasive index”), the authors were
able to separate patients with and without 3-vessel and/or left
main CAD using EBCT. Also, Guerci et al (46) recently
studied 290 men and women undergoing coronary arteriog-
raphy for clinical indications and concluded that EBCT
scanning improved discrimination over conventional risk
factors in the identification of persons with angiographic
coronary disease. Because this study was conducted in a
symptomatic population with an angiographic end point, its
application is limited to such patients.
Comparison With Other Tests for Diagnosis
It is appropriate to compare EBCT with the older diagnostic
modalities, particularly the standard ECG exercise test, which
is a mature, established technology. The equipment and
personnel for performing stress electrocardiography, myocar-
dial perfusion imaging, and echocardiography are readily
available. Also, for the exercise test, the equipment is
relatively inexpensive, so that replacing or updating it is not
a major cost factor. The ECG exercise test, like the echocar-
diogram, can be performed in the doctor’s office and does not
require injections or exposure to radiation. Furthermore, it
can determine the degree of disability and impairment to
quality of life, as well as be the first step in rehabilitation and
alteration of an important risk factor (physical inactivity).
Some of the newer stress imaging modalities have the
advantage of being able to localize ischemia as well as
diagnose CHD when the baseline ECG negates ST analysis
(eg, .1-mm ST depression, left bundle-branch block, or
Wolff-Parkinson-White syndrome). The alternatives to the
ECG exercise test also have the advantage of not requiring
the patient to exercise and are particularly valuable for the
clinical assessment of those who cannot walk. However,
although the newer technologies appear to have better
diagnostic characteristics, this is not always the case,
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particularly when factors other than ST-segment changes
during the exercise test are used in scores (47).
Test evaluation has been advanced by the writings of
Feinstein and associates (48,49), as well as others (50),
resulting in an improved ability to evaluate studies of test
characteristics. Many researchers have applied these guide-
lines along with meta-analysis to obtain a consensus on the
diagnostic characteristics of the available tests for angio-
graphic CHD (51,52). Table 4 presents some of the results
using meta-analysis and data from multiple studies.
Because sensitivity and specificity are inversely related
and are altered by the chosen cut point for normal versus
abnormal results, the predictive accuracy (percentage of
patients correctly classified as having normal and abnormal
results) is a convenient way to compare tests. For instance,
although the sensitivity and specificity for exercise testing
and EBCT are nearly opposite, the predictive accuracy of the
tests is similar. This means that altering their cut points (ie,
lowering the amount of ST-segment depression or raising the
coronary artery calcium score) would result in similar sensi-
tivities and specificities. Because predictive accuracy refers
to the number of individuals correctly classified of 100 tested,
simple comparison of the predictive accuracy provides an
estimate of the number of additional patients classified by
substituting one test for another. However, this does assume
a disease prevalence of 50% as the intermediate probability
for appropriate use of diagnostic tests (ie, predictive accuracy
is affected by disease prevalence).
Exercise ECG Test
Gianrossi et al (53) investigated the variability of the reported
diagnostic accuracy of the exercise ECG for CAD by apply-
ing meta-analysis. One hundred forty-seven consecutively
published reports involving 24 074 patients who underwent
both coronary angiography and exercise testing were summa-
rized and the results entered into a computer spreadsheet.
Wide variability in sensitivity and specificity was found
(mean sensitivity was 68%, with a range of 23% to 100% and
a standard deviation of 16%; mean specificity was 77%, with
a range of 17% to 100% and a standard deviation of 17%).
The median predictive accuracy (percentage of total true-
positives and true-negatives) was ’73%.
To more accurately portray the performance of the exercise
test, only the results in 41 of the original 147 studies were
reanalyzed. These 41 studies excluded patients with a prior
myocardial infarction, fulfilling one of the criteria for evalu-
ating a diagnostic test, and provided all of the numbers for
calculating test performance. These 41 studies, including
.10 000 patients, demonstrated a lower mean sensitivity of
68% and a lower mean specificity of 74%; this means that
there also was a lower predictive accuracy (69% rather than
73%). In 2 studies (54,55) in which workup bias was reduced
by design, fulfilling the other major criteria, the sensitivity
was ’50% and the specificity 90%, with the predictive
accuracy remaining at 70%. Workup bias was not removed in
any of the other studies of diagnostic tests.
Myocardial Perfusion Imaging
and Echocardiography
Fleischmann and associates (56) reviewed the contemporary
literature to compare the diagnostic performance of exercise
echocardiography and exercise nuclear perfusion scanning in
the diagnosis of CAD. Studies published between January
1990 and October 1997 identified from a MEDLINE search,
bibliographies of reviews and original articles, and sugges-
tions from experts in each area were considered if they
discussed exercise echocardiography and/or exercise perfu-
sion imaging with thallium or sestamibi (primarily SPECT)
for detection or evaluation of CAD; if data on coronary
angiography were presented as the reference test; and if the
absolute numbers of true-positive, false-negative, true-
negative, and false-positive observations were available or
derivable from the data presented. Studies performed exclu-
sively in patients after myocardial infarction, percutaneous
transluminal coronary angioplasty, or coronary artery bypass
grafting or in those with recent unstable coronary syndromes
were excluded. Two reviewers used a standardized spread-
sheet to independently extract clinical variables, technical
factors, and test performance. Discrepancies were resolved by
consensus. Forty-four articles (not unique patient data sets)
met inclusion criteria: 24 reported exercise echocardiography
results in 2637 patients with a weighted mean age of 59 years,
of whom 69% were men, 66% had angiographic coronary
disease, and 20% had prior myocardial infarction; and 27
TABLE 4. Comparison of Exercise Testing and Add-Ons or Other Test Modalities
Grouping
No. of
Studies
Total No. of
Patients
Sensitivity,
%
Specificity,
%
Predictive
Accuracy, %
Meta-analysis of standard exercise ECG 147 24 047 68 77 73
Excluding MI patients 41 11 691 67 74 69
Limiting workup bias 2 2350 50 90 69
Meta-analysis of exercise test scores 24 11 788 80
Perfusion scintigraphy 2 28 751 89 80 89
Exercise echocardiography 58 5000 85 79 83
Nonexercise stress tests
Pharmacological stress scintigraphy 11 ,1000 85 91 87
Dobutamine echocardiography 5 ,1000 88 84 86
EBCT 16 3683 91 49 70
MI indicates myocardial infarction.
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reported exercise SPECT in 3237 patients, of whom 70%
were men, 78% had angiographic coronary disease, and 33%
had prior myocardial infarction. In pooled data weighted by
the sample size of each study, exercise echocardiography had
a sensitivity of 85% (95% CI 83% to 87%) with a specificity of
77% (95% CI 74% to 80%). Exercise perfusion yielded a similar
sensitivity of 87% (95% CI 86% to 88%) but a lower specificity
of 64% (95% CI 60% to 68%). Data from 2 registries on SPECT
imaging in .20 000 patients revealed sensitivity and specificity
values of 89% and 80%, respectively.
In summary, it is difficult to determine with certainty from
our meta-analysis whether the studies of EBCT suffer from
limited challenge and workup bias, as is frequently found in
studies of diagnostic procedures. However, the 16 studies
averaged in Tables 2 and 3 demonstrated a high sensitivity
but a low specificity, with a predictive accuracy of ’70% or
less. These data for EBCT can be compared with the results
from meta-analyses of other diagnostic procedures. A posi-
tive test will clearly lead to increased patient anxiety, even if
the clinician chooses to disregard it or to use it to focus on
risk factor modification, and even if a subsequent test is
negative. A positive test can also lead to coronary angiogra-
phy and revascularization, as demonstrated in the follow-up
series on asymptomatic patients. Most importantly, most
clinicians who perform diagnostic testing are actually also
using that test result to stratify the patient according to risk.
Existing modalities such as exercise testing, perfusion scin-
tigraphy, and exercise echocardiography are extraordinarily
well validated with respect to prognostic implications, as
demonstrated in the previous sections on asymptomatic CAD;
EBCT is not as well studied. Moreover, given the tremendous
prognostic information that is implicit in exercise capacity,
even when it is combined with imaging, EBCT starts with a
disadvantage compared with existing modalities in symptom-
atic patients who can exercise.
Although adjusting the cut point for calcium density
(coronary artery calcium score) alters the sensitivity and
specificity, the EBCT is not superior to other currently
available diagnostic procedures for diagnosis of angiographic
CHD. Direct comparisons of EBCT studies with other com-
monly used tests for detecting CHD have revealed modest
correlations of abnormal test results (57). Although EBCT is
a relatively inexpensive test, its reported low specificity for
obstructive CAD may lead to unnecessary additional workups
in a patient with a positive calcium score. However, the true
specificity may be somewhat higher than our meta-analysis
suggests, and there is no published evidence that additional
testing necessarily results from the use of EBCT.
VII. Assessment of Progression or Regression
of CHD by EBCT
Significant benefit would be achieved if there were a clini-
cally applicable, noninvasive method by which changes in
plaque characteristics or volume could be monitored during
pharmacological interventions. There have been several pub-
lished studies (58–60) that have examined progression,
stabilization, and regression of coronary artery lesions during
aggressive risk factor modification, most notably lipid-
lowering therapy. These data have suggested that there may
be minimal to mild changes in angiographic lumen caliber
associated with pharmacological therapy, but that these are
significantly less than the subsequent clinical benefits found
in the active-treatment group. It has been postulated that
lipid-lowering therapy with the HMG-CoA (b-hydroxy-b-
methylglutaryl–coenzyme A) reductase inhibitors likely re-
sults in “stabilization” of lipid-rich plaques and/or reduction
in neointimal inflammation through a variety of mechanisms
that remain incompletely defined (61).
Quantification of coronary artery calcium has been shown
to be reflective of the total atherosclerotic plaque burden
(23,62). This quantification can be determined in a straight-
forward fashion by use of EBCT. Therefore, the use of EBCT
offers the potential to follow disease progression, stabiliza-
tion, and possible regression through serial imaging. How-
ever, for this to become a clinical reality, the reproducibility
of EBCT calcium scoring must be acceptable and the pro-
gression of disease in general should be greater than the error
between successive EBCT scoring examinations. Further-
more, there must be evidence that EBCT is useful in serial
evaluations of plaque disease with and without specific
therapy.
There have been several studies that evaluated reproduc-
ibility of EBCT scanning and conventional scoring by the
Agatston method (17). Although calculation of the total
calcium score from a single EBCT examination has been
reported to have excellent interobserver and intraobserver
reliability (63), reproducibility from 2 scanning runs (inter-
scan reliability) has varied from poor to only fair, depending
on the laboratory and the method of calculation
(34,36,37,64). It has ranged from 14% to 51% variability
(differences/mean).
Differences for total calcium scores between scan 1 and
scan 2 taken only a few minutes apart are readily apparent,
but they are generally small if scanning is performed in a
skilled clinical laboratory. When studies in which there is a
.10% to 15% discrepancy between the 2 calcium scores are
carefully examined, clear reasons are apparent when the total
calcium scores exceed 10. Greater percent changes are seen
with lower scores. In one study (4), the variability with a
6-mm-thickness scan protocol reduced the retest variability
by 50%.
Callister and associates (65) evaluated an alternative
method of determining EBCT calcium score by quantifying
the actual volume of plaque analogous to that possible in
prior histological investigations (23,65). Callister et al exam-
ined 52 paired EBCT scans taken 5 minutes apart and
calculated a total calcium volume score (CVS) versus the
traditional Agatston calcium score. They concluded that use
of CVS showed better reproducibility than the traditional
Agatston calcium score, and its variability was considerably
smaller than the measured calcium score increase found in
untreated patients at the end of 1 year.
There are limited data available on the potential influence
of pharmacological intervention on the assessment of plaque
progression by EBCT. Callister and colleagues (66) retro-
spectively evaluated serial EBCT scans in 149 asymptomatic,
hyperlipidemic patients (61% men, aged 32 to 75 years) for
serial changes in plaque burden. Each patient had been
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referred for EBCT screening, none had documented CAD,
and none were receiving HMG-CoA reductase inhibitors at
baseline. Each was found to have documented coronary
calcium on the initial scan and was referred back to his or her
physician for follow-up. One hundred five patients (70%)
were subsequently prescribed a statin medication, and 44
(30%) were left untreated. After 1 year, a repeat EBCT scan
was done to assess possible changes from the baseline EBCT
calcium study. For this investigation, the CVS method orig-
inally described by their laboratory (65) was used. Treated
patients maintained a mean LDL cholesterol level of 114623
mg/dL, whereas untreated patients had a mean value of
147622 mg/dL. The average CVS change in the treated
group over the follow-up period (13.760.6 months) was
5628%, whereas for the untreated group, it was 52636%
(P,0.001). The treated group was further divided into 2
groups: those who achieved a target LDL of ,120 mg/dL and
those who achieved a target LDL of $120 mg/dL. In the
treated group with the lower LDL level, there was a net
change in CVS between baseline and follow-up of 27623%,
whereas in the treated group with the higher LDL level, there
was a net change in CVS of 25622% (P,0.01). These data
suggest that plaque burden as assessed by EBCT can be
influenced by the level of aggressiveness of antilipidemic
therapy. Furthermore, these data are consistent with prior
angiographic studies that suggest that there can be a net
regression of coronary disease as a result of long-term statin
therapy. However, the sample size was small, and follow-up
was short. Additional data are required to determine whether
these findings can be corroborated and especially whether
these presumed changes in plaque burden are reflected in the
alteration of cardiac events in more rigorous randomized,
controlled clinical trials.
VIII. Cost-Effectiveness of EBCT
Increasingly, there is a demand to demonstrate that any new
test or form of therapy improves patient outcome; this is often
approached by performing a cost-effectiveness analysis.
Cost-effectiveness analyses can be used to compare compet-
ing tests or forms of therapy and can offer the result as a
single number, the cost-effectiveness ratio, commonly ex-
pressed in cost per quality-adjusted life-year gained (67). This
ratio for a specific procedure or therapy may then be
compared with other ratios for other medical interventions
competing for scarce healthcare resources. To perform this
analysis, it is necessary to be able to measure both the effect
and cost of a test or form of therapy. To make these
measurements in cost per quality-adjusted life-year gained, it
is necessary to measure results over a lifetime or, more
realistically, extrapolate short-term results to a lifetime. In the
case of EBCT, there is uncertainty concerning even the
short-term gain. To establish truly comparable groups that
would provide comparable cost and outcome data, it would be
necessary to conduct randomized trials comparing EBCT
with a competing method. However, such trials would be
difficult and expensive to conduct successfully. Furthermore,
short-term trials might provide little information concerning
long-term benefit.
When testing is considered, the recognition that random-
ized trials are not practical has led to the use of decision-
analytic methods (that is, simulations) to try to estimate the
cost for some benefit achieved (68). The fundamental limi-
tation with a simulation is that for a diagnostic modality, the
downstream decision trees can become quite complicated
depending on how test outcome affects subsequent decision
making. EBCT in particular has not been used extensively
and is a new technology with few data on the necessary
resources and expected outcomes from test results. In such
simulations, the cost-effectiveness analysis may bear little
relation to reality. To avoid this problem, the benefit exam-
ined may be something less apparent than quality-adjusted
life-years gained.
Given the difficulty of conducting randomized trials, the
inherently limited nature of simulations, and the paucity of
information of any kind at present, there is a limit as to
what can be stated concerning the cost-effectiveness of
EBCT. Rumberger et al (69) assessed the cost and effec-
tiveness of EBCT as an approach to diagnosis of CAD “in
theoretical analyses based on mathematical models.” He
used published sensitivity and specificity, and disease
prevalence was tested by angiography alone, treadmill
testing, stress echocardiography, stress thallium scans, or
predetermined EBCT calcium score cut points followed by
angiography if needed. The data developed support the use
of EBCT as a minimal cost (short-term) and maximum
effectiveness approach to the diagnosis of obstructive
CAD in specific subsets of the general population. This
test was a simulation and was limited by the use of cost per
diagnosis achieved, rather than the marginal cost-
effectiveness compared with a competing choice; however,
it does provide preliminary information to help guide
decision making. The problems of defining cost-
effectiveness of EBCT are compounded by the several
potential uses of EBCT. More assumptions must be made
to define cost-effectiveness for diagnosis of early disease
or atherosclerotic burden, and long-term outcome must be
considered almost by necessity. Detailed decision-analytic
models to examine the cost-effectiveness of EBCT both for
diagnosis of coronary disease and for its ability to predict
and modify the outcome of early disease are under devel-
opment. Even these models will be limited both by the
paucity of data and the difficulty in realistically defining
downstream decisions. Future research should, at the very
least, offer improved simulations to help define those
patients and uses for which EBCT is cost-effective, per-
haps using proxies for long-term outcome when possible,
but using life-years gained or quality-adjusted life-years
gained when appropriate.
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